TRAW Stock Overview
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Traws Pharma, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.63 |
52 Week High | US$1.45 |
52 Week Low | US$0.55 |
Beta | 1.35 |
1 Month Change | -29.72% |
3 Month Change | -10.49% |
1 Year Change | -45.94% |
3 Year Change | -94.20% |
5 Year Change | -98.96% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Rate
Mar 09Here's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Situation
Apr 22Onconova Therapeutics (NASDAQ:ONTX) Is In A Good Position To Deliver On Growth Plans
Jul 27Will Onconova Therapeutics (NASDAQ:ONTX) Spend Its Cash Wisely?
Mar 21Companies Like Onconova Therapeutics (NASDAQ:ONTX) Are In A Position To Invest In Growth
Dec 06Onconova Therapeutics names Mark Gelder as chief medical officer
Jun 01Onconova Therapeutics announces $8.7M registered direct offering
Jan 07Onconova cleared to start Phase 1 trial for cancer therapy
Dec 24Onconova Therapeutics EPS in-line, misses on revenue
Nov 12Shareholder Returns
TRAW | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -9.1% | 0.08% | 1.2% |
1Y | -45.9% | 13.2% | 24.9% |
Price Volatility
TRAW volatility | |
---|---|
TRAW Average Weekly Movement | 9.6% |
Pharmaceuticals Industry Average Movement | 9.8% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TRAW's share price has been volatile over the past 3 months.
Volatility Over Time: TRAW's weekly volatility (10%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 18 | Werner Cautreels | www.onconova.com |
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa.
Traws Pharma, Inc. Fundamentals Summary
TRAW fundamental statistics | |
---|---|
Market cap | US$13.34m |
Earnings (TTM) | -US$18.95m |
Revenue (TTM) | US$226.00k |
59.0x
P/S Ratio-0.7x
P/E RatioIs TRAW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TRAW income statement (TTM) | |
---|---|
Revenue | US$226.00k |
Cost of Revenue | US$0 |
Gross Profit | US$226.00k |
Other Expenses | US$19.17m |
Earnings | -US$18.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.90 |
Gross Margin | 100.00% |
Net Profit Margin | -8,384.07% |
Debt/Equity Ratio | 0% |
How did TRAW perform over the long term?
See historical performance and comparison